Dear Doctors: I am 75 years old, and two years ago, I was diagnosed with bullous pemphigoid. I understand this is an autoimmune problem. I also understand that this is more common in older people. I ...
Please provide your email address to receive an email when new articles are posted on . 50% of patients treated with dupilumab achieved complete remission of blistering lesions. Sixteen patients ...
Donna Culton, MD, University of North Carolina at Chapel Hill, outlines diagnosing autoimmune blistering diseases. Persistent, intensely itchy rashes in older adults are often written off as eczema or ...
Please provide your email address to receive an email when new articles are posted on . If approved, Dupixent would be the first and only targeted medicine to treat bullous pemphigoid in the U.S. The ...
A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...
The many different types of BP can cause difficulty in diagnosis, especially in the variants that present similarly to other dermatological diseases. Generalized erythroderma BP (GEBP) presents very ...
DUBLIN--(BUSINESS WIRE)--The "Bullous pemphigoid - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering. The "Bullous Pemphigoid - Pipeline Insight, 2023" report ...
Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary ...
Regeneron and Sanofi Announce FDA Approval of Dupixent for Treatment of Bullous Pemphigoid in Adults
The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for treating adults with bullous pemphigoid (BP), a chronic and debilitating skin disease primarily affecting the elderly ...
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...
Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results